Announcements
Trials
Browse
Landscape
Eligibility
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Adenocarcinoma
×
Epirubicin
×
Clear all
Filters
3
NCT00215644
2018-11-02
MATRIX EG
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
72 enrolled
7 charts